Story

Moderna Stock Rises on Historic FDA Approval for mRNA Flu Vaccine

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Moderna Stock Rises on Historic FDA Approval for mRNA Flu Vaccine
Text size
Background

Moderna (MRNA) shares rose 3.7% in pre-market trading after the U.S. Food and Drug Administration (FDA) approved its seasonal influenza vaccine, mFLUSIVA (mRNA-1010). The decision marks a significant milestone as it is the first time an mRNA-based flu shot has been cleared for use in the United States.

A Landmark Approval

The FDA's approval covers adults aged 50 and older, with a distinction based on age group. The agency granted full approval for individuals aged 50 to 64, while those 65 and older received accelerated approval. This accelerated status is contingent on a confirmatory postmarketing study, according to the announcement.

The approval is based on data from a comprehensive Phase 3 clinical trial that involved more than 40,000 participants across 11 countries. In a statement, CEO Stéphane Bancel said the approval "demonstrates the continued strength and versatility of our mRNA platform," validating its potential beyond the company's well-known COVID-19 vaccine.

Path to Market

The regulatory journey for mFLUSIVA was not straightforward. The FDA had previously issued a refusal-to-file letter in February 2026. Moderna subsequently restructured its application by age group, which ultimately led to a unanimous 9-0 vote in favor from an FDA advisory committee in June 2026.

Sample IUX Markets – In-articleAd

Moderna stated it expects to begin supplying the vaccine to select U.S. retailers within weeks, positioning it for the upcoming flu season. The company also noted that mFLUSIVA is currently under regulatory review in the European Union, Canada, and Australia.

Analyst Outlook and Market Context

Despite the landmark approval, Wall Street's reaction has been measured. The broader analyst consensus on Moderna stock remains a Hold, with an average price target near $52, as cited by Investing.com. Analysts point to uncertainties around the near-term revenue ramp-up and potential insurance coverage challenges.

The stock's pre-market gain was a company-specific event, standing in contrast to the broader market, where the Nasdaq Composite was down 0.5%. This highlights that the rally was driven by the regulatory news rather than overall market or sector momentum.

Read next

More on Stocks
Back to latest news

LATEST